9PHR | pdb_00009phr

BTB modified at C151 with monobimane

  • Classification: SIGNALING PROTEIN
  • Organism(s): Homo sapiens
  • Expression System: Escherichia coli
  • Mutation(s): Yes 

  • Deposited: 2025-07-09 Released: 2025-11-19 
  • Deposition Author(s): Ragwan, E.R., Kung, Y., Eggler, A.L.
  • Funding Organization(s): National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS), Department of Energy (DOE, United States), Other private

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.80 Å
  • R-Value Free: 
    0.282 (Depositor), 0.279 (DCC) 
  • R-Value Work: 
    0.234 (Depositor), 0.233 (DCC) 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.0 of the entry. See complete history


Literature

KEAP1 C151 active site catalysis drives electrophilic signaling to upregulate cytoprotective enzyme expression.

Schnell, M.R.Zhai, T.Ragwan, E.R.Jung, H.Zhang, J.Lagalante, A.F.Kung, Y.Kraut, D.A.Huang, Z.Eggler, A.L.

(2025) Redox Biol 88: 103906-103906

  • DOI: https://doi.org/10.1016/j.redox.2025.103906
  • Primary Citation of Related Structures:  
    9PHR

  • PubMed Abstract: 

    Cells mount a detoxification, antioxidant, and anti-inflammatory response to electrophiles, mediated by the NRF2 transcription factor. Electrophilic NRF2 activators are used to treat diverse chronic diseases. While the majority of NRF2 activators target C151 of KEAP1, the primary NRF2 repressor, it is unknown how diverse electrophiles favor this particular cellular cysteine. One hypothesis is that the pK a of C151 is lowered by surrounding basic residues, resulting in a higher population of the reactive thiolate. We show that the pK a of C151 is 6.9, providing optimal reactivity at physiological pH, using the fluorogenic, thiol-reactive electrophile monobromobimane. Surprisingly, monobromobimane reacts with C151 much faster than with a small-molecule thiolate. NRF2 activators in clinical use and trials (omaveloxolone, bardoxolone methyl, and sulforaphane) readily compete with monobromobimane for C151. A BTB-monobimane crystal structure shows no specific orientation in the active site after covalent addition. A 4D flexible BTB model based on seven crystal structures was used to dock mBBr and NRF2 activators into the active site to obtain poses of the pre-covalent enzyme-substrate complexes. They reveal an active site around C151 that accommodates structurally diverse activators using largely hydrophobic interactions, with a hydrogen bond orienting their electrophilic carbons within ∼3-5 Å of C151 for a catalytic proximity effect. In addition, our biochemical and docking results suggest a critical catalytic role for hydrogen bonding to the oxygen of an α,β unsaturated carbonyl, which could both increase carbon electrophilicity and stabilize the negative charge in the transition state. Overall, this work suggests enzymatic catalysis is the primary reason that C151 acts as a sensor cysteine for therapeutic, electrophilic NRF2 activators, highly favoring reaction with C151 over other cellular cysteines. The kinetic targeting of electrophiles such as sulforaphane and omaveloxolone to the C151 active site provides an explanation for how electrophilic compounds can be selective pharmacological agents.


  • Organizational Affiliation
    • Department of Chemistry and Biochemistry, Villanova University, Villanova, PA, 19085, USA; Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, 19104, USA.

Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Kelch-like ECH-associated protein 1131Homo sapiensMutation(s): 1 
Gene Names: KEAP1INRF2KIAA0132KLHL19
UniProt & NIH Common Fund Data Resources
Find proteins for Q14145 (Homo sapiens)
Explore Q14145 
Go to UniProtKB:  Q14145
PHAROS:  Q14145
GTEx:  ENSG00000079999 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ14145
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
9UM (Subject of Investigation/LOI)
Query on 9UM

Download Ideal Coordinates CCD File 
B [auth A]3-(bromomethyl)-2,5,6-trimethyl-1H,7H-pyrazolo[1,2-a]pyrazole-1,7-dione
C10 H11 Br N2 O2
AHEWZZJEDQVLOP-UHFFFAOYSA-N
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.80 Å
  • R-Value Free:  0.282 (Depositor), 0.279 (DCC) 
  • R-Value Work:  0.234 (Depositor), 0.233 (DCC) 
Space Group: P 65 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 42.976α = 90
b = 42.976β = 90
c = 266.628γ = 120
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata reduction
XDSdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)United StatesP30GM133893
Department of Energy (DOE, United States)United StatesKP1605010
Other private--

Revision History  (Full details and data files)

  • Version 1.0: 2025-11-19
    Type: Initial release